A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

Randomized, double-blind, placebo-controlled, parallel-group, multicenter study followed by an open-label treatment phase (OLTP). To evaluate the effect of erenumab (AMG 334) compared to placebo on the change from baseline in monthly migraine days.

Study Overview

• Status: Completed
• Conditions: Migraine
• Intervention / Treatment: Drug: Placebo; Drug: Erenumab; Drug: Erenumab

Detailed Description

This is a Phase 2, randomized, double-blind, placebo-controlled study in participants with episodic migraine. The study's double blind treatment phase (DBTP) is designed to evaluate if treatment with erenumab once a month for 6 months compared with placebo is effective in reducing the mean monthly migraine days. Additionally, this study will continue to evaluate the efficacy and safety of erenumab during the OLTP where participants will continue to receive active treatment monthly.

The study also includes a clinical home use (CHU) sub-study to assess a participant's ability to self-administer 140 mg of erenumab. Participants will be randomized 1:1 to use either 2 pre-filled 70 mg/mL autoinjector (AI)/pens or 1 pre-filled 140 mg/mL AI/pen. Participation in the substudy is optional, and no additional samples will be collected for the sub-study.

After implementation of Protocol Amendment 2, the dose of erenumab in the OLTP increased from 70 mg to 140 mg QM. Participants who had already completed week 48 remain on 70 mg QM, participants not yet starting the OLTP, or not yet completing the week 48 visit receive erenumab 140 mg QM for the remainder of the OLTP.

• Study Type: Interventional
• Enrollment (Actual): 475
• Phase: Phase 2

Contacts and Locations

Study Locations

• Japan
  • Chiba
    • Kamogawa-shi, Chiba, Japan, 296-0041
      • Research Site
  • Ehime
    • Saijo-shi, Ehime, Japan, 793-0030
      • Research Site
  • Gunma
    • Ota-shi, Gunma, Japan, 373-8585
      • Research Site
  • Hiroshima
    • Hiroshima-shi, Hiroshima, Japan, 730-8518
      • Research Site
  • Hokkaido
    • Sapporo-shi, Hokkaido, Japan, 063-0005
      • Research Site
    • Sapporo-shi, Hokkaido, Japan, 060-8570
      • Research Site
    • Sapporo-shi, Hokkaido, Japan, 060-0004
      • Research Site
  • Hyogo
    • Kobe-shi, Hyogo, Japan, 658-0064
      • Research Site
  • Ibaraki
    • Tsukuba-shi, Ibaraki, Japan, 305-8576
      • Research Site
  • Ishikawa
    • Kahoku-gun, Ishikawa, Japan, 929-0342
      • Research Site
  • Iwate
    • Morioka-shi, Iwate, Japan, 020-8505
      • Research Site
  • Kagoshima
    • Kagoshima-shi, Kagoshima, Japan, 892-0844
      • Research Site
  • Kanagawa
    • Kawasaki-shi, Kanagawa, Japan, 211-8533
      • Research Site
    • Kawasaki-shi, Kanagawa, Japan, 216-8511
      • Research Site
    • Kawasaki-shi, Kanagawa, Japan, 211-8588
      • Research Site
  • Kumamoto
    • Kumamoto-shi, Kumamoto, Japan, 861-2101
      • Research Site
    • Kumamoto-shi, Kumamoto, Japan, 862-8505
      • Research Site
  • Kyoto
    • Kyoto-shi, Kyoto, Japan, 600-8811
      • Research Site
  • Miyagi
    • Sendai-shi, Miyagi, Japan, 982-0014
      • Research Site
  • Osaka
    • Osaka-shi, Osaka, Japan, 556-0017
      • Research Site
    • Osakasayama-shi, Osaka, Japan, 589-8511
      • Research Site
    • Toyonaka-shi, Osaka, Japan, 560-0012
      • Research Site
  • Saga
    • Saga-shi, Saga, Japan, 840-0806
      • Research Site
  • Saitama
    • Iruma-gun, Saitama, Japan, 350-0495
      • Research Site
    • Saitama-shi, Saitama, Japan, 338-8577
      • Research Site
    • Tokorozawa-shi, Saitama, Japan, 359-1141
      • Research Site
  • Shizuoka
    • Shizuoka-shi, Shizuoka, Japan, 420-0853
      • Research Site
  • Tochigi
    • Shimotsuga-gun, Tochigi, Japan, 321-0293
      • Research Site
  • Tokyo
    • Bunkyo-ku, Tokyo, Japan, 113-8603
      • Research Site
    • Bunkyo-ku, Tokyo, Japan, 113-8431
      • Research Site
    • Chofu-shi, Tokyo, Japan, 182-0006
      • Research Site
    • Chuo-ku, Tokyo, Japan, 104-8560
      • Research Site
    • Hachioji-shi, Tokyo, Japan, 192-0032
      • Research Site
    • Minato-ku, Tokyo, Japan, 108-8642
      • Research Site
    • Minato-ku, Tokyo, Japan, 106-6106
      • Research Site
    • Shibuya-ku, Tokyo, Japan, 151-0051
      • Research Site
    • Shinjuku-ku, Tokyo, Japan, 160-0017
      • Research Site
    • Shinjuku-ku, Tokyo, Japan, 160-8582
      • Research Site
  • Tottori
    • Yonago-city, Tottori, Japan, 683-8504
      • Research Site
  • Toyama
    • Toyama-shi, Toyama, Japan, 930-0803
      • Research Site
    • Toyama-shi, Toyama, Japan, 930-0194
      • Research Site
  • Yamaguchi
    • Hofu-shi, Yamaguchi, Japan, 747-0802
      • Research Site
    • Yamaguchi-shi, Yamaguchi, Japan, 754-0002
      • Research Site
  • Yamanashi
    • Kai-shi, Yamanashi, Japan, 400-0124
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria to be assessed prior to entering the subject into the initial screening and/or baseline phase:

• Provided informed consent prior to initiation of any study-specific activities/procedures
• History of migraine (with or without aura) for ≥ 12 months prior to screening according to the International Headache Society (IHS) Classification The International Classification of Headache Disorders (ICHD)-3 (Headache Classification Committee of the IHS, 2013),
• Migraine frequency: ≥ 4 and < 15 migraine days per month on average across the 3 months prior to screening,
• Headache frequency: < 15 headache days per month on average across the 3 months prior to screening.

Inclusion Criteria to be assessed during the baseline phase and confirmed prior to randomizing the subject into the double-blind treatment phase:

• Demonstrated at least 80% compliance with the electronic Diary (eDiary),
• Migraine frequency: ≥ 4 and < 15 migraine days during the baseline phase based on the eDiary calculations,
• Headache frequency: < 15 headache days during the baseline phase based on the eDiary calculations.

Inclusion Criteria for the Clinical Home Use (CHU) Substudy:

- Subjects must have provided informed consent for the substudy. Subjects enrolling in the CHU substudy must have received open-label 140 mg erenumab for at least 1 dose.

Exclusion Criteria:

• Older than 50 years of age at migraine onset,
• History of cluster headache or hemiplegic migraine headache,
• Unable to differentiate migraine from other headaches,
• No therapeutic response with > 2 of the following 7 medication categories for prophylactic treatment of migraine after an adequate therapeutic trial: Category 1: Divalproex sodium, sodium valproate, Category 2: Topiramate, Category 3: Beta blockers (for example: atenolol, bisoprolol, metoprolol, nadolol, nebivolol, pindolol, propranolol, timolol), Category 4: Tricyclic antidepressants (for example: amitriptyline, nortriptyline, protriptyline),Category 5: Serotonin-norepinephrine reuptake inhibitors (for example: venlafaxine, desvenlafaxine, duloxetine, milnacipran), Category 6: Flunarizine, verapamil, lomerizine, Category 7: Lisinopril, candesartan,
• Used a prohibited medication, device or procedure within 2 months prior to the start of the baseline phase or during the baseline phase,
• Received botulinum toxin in the head and/or neck region within 4 months prior to the start of the baseline phase or during the baseline phase,
• Taken the following for any indication in any month during the 2 months prior to the start of the baseline phase: Ergotamines or triptans on ≥ 10 days per month, or Simple analgesics (nonsteroidal anti-inflammatory drugs [NSAIDs], acetaminophen) on ≥ 15 days per month, or Opioid- or butalbital-containing analgesics on ≥ 4 days per month,
• Anticipated to require any excluded medication, device or procedure during the study,
• Active chronic pain syndromes (such as fibromyalgia and chronic pelvic pain),
• History of major psychiatric disorder (such as schizophrenia and bipolar disorder), or current evidence of depression based on a Beck Depression Inventory (BDI)-II total score > 19 at screening. Subjects with anxiety disorder and/or major depressive disorder are permitted in the study if they are considered by the investigator to be stable and are taking no more than 1 medication for each disorder. Subjects must have been on a stable dose within the 3 months prior to the start of the baseline phase,
• History of seizure disorder or other significant neurological conditions other than migraine. Note: A single childhood febrile seizure is not exclusionary,
• Malignancy within the 5 years prior to screening, except non melanoma skin cancers, cervical or breast ductal carcinoma in situ,
• Human immunodeficiency virus (HIV) infection by history,
• Hepatic disease by history, or total bilirubin (TBL) ≥ 2.0 x upper limit of normal (ULN) or alanine transaminase (ALT) or aspartate aminotransferase (AST) ≥ 3.0 x ULN, as assessed by the central laboratory at initial screening, or evidence of acute or chronic hepatitis B or hepatitis C virus. Hepatitis status will be evaluated by testing for hepatitis B surface antigen (HepBsAg), total hepatitis B core antibody (HepBcAb) and hepatitis C antibody by the central laboratory at initial screening. Polymerase chain reaction (PCR) should be performed to confirm active disease only if total HepBcAb is positive and HepBsAg is negative or if C antibody is positive,
• Myocardial infarction, stroke, transient ischemic attack (TIA), unstable angina, or coronary artery bypass surgery or other revascularization procedure within 12 months prior to screening,
• History or evidence of any other unstable or clinically significant medical condition that, in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion,
• Subject has any clinically significant vital sign, laboratory, or electrocardiogram (ECG) abnormality during screening that, in the opinion of the investigator, could pose a risk to subject safety or interfere with the study evaluation,
• The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior or endorsing items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) assessed at screening,
• Evidence of drug or alcohol abuse or dependence within 12 months prior to screening, based on medical records, patient self-report, or positive urine drug test performed during screening (with the exception of prescribed medications such as opioids or barbiturates),
• Pregnant or breastfeeding, or is a female expecting to conceive during the study, including through 16 weeks after the last dose of investigational product,
• Female subject of childbearing potential who is unwilling to use an acceptable method of effective contraception during treatment with investigational product through 16 weeks after the last dose of investigational product,
• Currently receiving treatment in another investigational device or drug study, or less than 90 days prior to screening since ending treatment on another investigational device or drug study(-ies),
• Known sensitivity to any component of the investigational product (Refer to the Investigational Product Instruction Manual [IPIM] for details),
• Previously randomized into an erenumab study,
• Member of investigational site staff or relative of the investigator,
• Unlikely to be able to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (eg, independent completion of eDiary items) to the best of the subject's and investigator's knowledge.

Exclusion Criteria for the CHU Substudy:

- Unreliability as a study participant based on the investigator's (or designee's) knowledge of the subject (eg, unwillingness to adhere to the protocol, unwilling to self-inject using an autoinjector (AI)/pen after review of the Instructions for Use). Subjects receiving erenumab 70 mg in the open-label phase are not eligible.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

7

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Double Blind Treatment Phase (DBTP): Placebo; Participants received placebo by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.	Drug: Placebo; placebo via subcutaneous injection
Experimental: DBTP: Erenumab 28 mg QM; Participants received erenumab 28 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.	Drug: Erenumab; erenumab via subcutaneous injection; Other Names: AMG 334, Aimovig™; Drug: Erenumab; erenumab via autoinjector (AI)/pen; Other Names: AMG 334, Aimovig™
Experimental: DBTP: Erenumab 70 mg QM; Participants received erenumab 70 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.	Drug: Erenumab; erenumab via subcutaneous injection; Other Names: AMG 334, Aimovig™; Drug: Erenumab; erenumab via autoinjector (AI)/pen; Other Names: AMG 334, Aimovig™
Experimental: DBTP: Erenumab 140 mg QM; Participants received erenumab 140 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.	Drug: Erenumab; erenumab via subcutaneous injection; Other Names: AMG 334, Aimovig™; Drug: Erenumab; erenumab via autoinjector (AI)/pen; Other Names: AMG 334, Aimovig™
Experimental: Open-Label Treatment Phase (OLTP): Erenumab 70-140 mg QM; Participants received an erenumab dose of 70 and/or 140 mg QM SC (depending on the participant's visit completion status after Institutional Review Board [IRB] approval of Protocol Amendment 2) in the OLTP for a total of 76 weeks.	Drug: Erenumab; erenumab via subcutaneous injection; Other Names: AMG 334, Aimovig™; Drug: Erenumab; erenumab via autoinjector (AI)/pen; Other Names: AMG 334, Aimovig™
Experimental: CHU Sub-Study: Two 70 mg/mL AI/pens; A subset of participants in the OLTP randomized to self administer erenumab via two 70 mg/mL autoinjector (AI)/pens on day 29 and day 57 of the CHU Sub-Study	Drug: Erenumab; erenumab via subcutaneous injection; Other Names: AMG 334, Aimovig™; Drug: Erenumab; erenumab via autoinjector (AI)/pen; Other Names: AMG 334, Aimovig™
Experimental: CHU Sub-Study: One 140 mg/mL AI/pen; A subset of participants in the OLTP randomized to self administer erenumab via one 140 mg/mL AI/pen on day 29 and day 57 of the CHU Sub-Study	Drug: Erenumab; erenumab via subcutaneous injection; Other Names: AMG 334, Aimovig™; Drug: Erenumab; erenumab via autoinjector (AI)/pen; Other Names: AMG 334, Aimovig™

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Mean Monthly Migraine Days at Months 4, 5 and 6	A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was a migraine with or without aura, lasting for ≥ 30 minutes, and meeting at least one of the following criteria: a) ≥ 2 of the following pain features: unilateral, throbbing, moderate to severe, exacerbated with exercise/physical activity; b) ≥ 1 of the following associated symptoms: nausea and/or vomiting, photophobia and phonophobia. Change from baseline was calculated using the mean monthly migraine days from months 4, 5 and 6 of the DBTP minus the number of migraine days during the 4-week baseline phase. Least squares (LS) mean was estimated using a generalized linear mixed model which included treatment, visit, treatment by visit interaction, stratification factor (current, prior only, or no prior/current treatment), and baseline value as covariates.	4-week baseline phase and months 4, 5 and 6 of DBTP.
CHU Sub-Study: Participant-Reported Outcome of Attempted Full-Dose Administration at Day 29 (Week 4) and Day 57 (Week 8)	On CHU day 29 and day 57, site staff interviewed sub-study participants and asked if they administered a full, partial, or no dose of erenumab (after explaining that a full dose means that the entire volume of the AI/pen was injected) and documented the participant's response in the electronic case report form. Data presented are the percentage of participants who reported "full administration," "not full administration," or "discontinued investigational product (ie, no dose)." (Day 1 of the CHU substudy occurred at any OLTP study visit [up to week 88] as long as the participant had previously received at least 1 OL dose of erenumab 140 mg.)	CHU day 29 (week 4) and day 57 (week 8)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With at Least a 50% Reduction From Baseline in Mean Monthly Migraine Days at Months 4, 5 and 6	A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was a migraine with or without aura, lasting for ≥ 30 minutes, and meeting at least one of the following criteria: a) ≥ 2 of the following pain features: unilateral, throbbing, moderate to severe, exacerbated with exercise/physical activity; b) ≥ 1 of the following associated symptoms: nausea and/or vomiting, photophobia and phonophobia. At least a 50% reduction from baseline in monthly migraine days was determined if: (mean monthly migraine days over the last three months of the DBTP minus baseline monthly migraine days) * 100 / baseline monthly migraine days, was less than or equal to -50%.	4-week baseline phase and months 4, 5 and 6 of DBTP.
Change From Baseline in Mean Monthly Acute Migraine-Specific Medication Treatment Days at Months 4, 5 and 6	An acute migraine-specific medication treatment day was defined as any calendar day during which the participant took a migraine-specific medication (ie, triptan or ergotamine-derivatives). The change from baseline was calculated using the mean monthly acute migraine-specific medication treatment days over the last three months (months 4, 5 and 6) of the DBTP minus the baseline monthly acute migraine-specific medication treatment days. LS mean was estimated using a generalized linear mixed model which included treatment, visit, treatment by visit interaction, stratification factor (prior/current treatment), and baseline value as covariates.	4-week baseline phase and months 4, 5 and 6 of DBTP.
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Discontinuations Due to TEAEs, and Fatal TEAEs During the DBTP	An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. A serious adverse event (SAE) is defined as an adverse event that meets at least 1 of the following serious criteria: fatal; life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4= life-threatening, grade 5=death).	From first dose of IP up to week 24
Number of Participants With TEAEs, Serious TEAEs, Discontinuations Due to TEAEs, and Fatal TEAEs During the OLTP	An AE is defined as any untoward medical occurrence in a clinical trial participant. An SAE is defined as an adverse event that meets at least 1 of the following serious criteria: fatal; life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Events were graded according to the NCI CTCAE version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4= life-threatening, grade 5=death).	From first dose of IP in the OLTP (week 24) through the end of the OLTP (week 100) plus 12 weeks
Number of Participants With TEAEs, Serious TEAEs, Discotninuations Due to TEAEs, Fatal TEAEs, and Adverse Device Effects During the CHU Sub-Study	An AE is defined as any untoward medical occurrence in a clinical trial participant. An SAE is defined as an adverse event that meets at least 1 of the following serious criteria: fatal; life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Events were graded according to the NCI CTCAE version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4= life-threatening, grade 5=death). TEAEs leading to discontinuation of IP are TEAEs leading to complete discontinuation of erenumab regardless of CHU IP or parent study IP.	CHU sub-study day 1 through day 85 (end of CHU sub-study). Day 1 of the CHU substudy occurred at any OLTP study visit (up to week 88) as long as the participant had previously received at least 1 OL dose of erenumab 140 mg.
Number of Participants With Post-Baseline Liver Function Test Abnormalities During the DBTP	Post-baseline is defined as any assessment done after the first dose of IP. Liver Function tests included alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBL). ULN=upper limit of normal.	From the first dose of study IP through the end of the DBTP (up to week 24)
Number of Participants With Post-Baseline Liver Function Test Abnormalities During the OLTP	Post-baseline is defined as any assessment done after the first dose of OLTP IP. Liver Function tests included alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBL). ULN=upper limit of normal.	From the first dose of OLTP IP (week 24) through the end of the OLTP (up to week 100)
Number of Participants With Blood Pressure Changes From Baseline in Categories at Week 24 During the DBTP	Participants with increases (↑) from baseline (BL) in diastolic blood pressure (DBP) and systolic blood pressure (SBP) at week 24 (Wk24) are presented.	Baseline (last assessment prior to first dose of IP), week 24
Number of Participants With Blood Pressure Changes From Pre-OLTP Baseline in Categories at Week 100 During the OLTP	Participants with increases (↑) from baseline (BL) in diastolic blood pressure (DBP) and systolic blood pressure (SBP) at week 100 (Wk100) are presented.	Pre-OLTP Baseline (last assessment prior to first dose of IP in OLTP), week 100
Number of Participants With Anti-Erenumab Antibodies During the Entire Study for Participants Who Received ≥ 1 Dose of Erenumab	Data are summarized by the treatment participants received during the double-blind treatment phase. Placebo participants may have received erenumab 70 mg or 140 mg during the OLTP. Baseline is defined as the last antibody assessment on or prior to the first dose of erenumab. Transient binding/neutralizing antibody responses are defined as a negative (neg) result at the participant's last timepoint tested among participants who developed binding/neutralizing antibodies post-baseline.	Baseline (first dose of erenumab) up to end of study (week 100) plus 12 weeks

Collaborators and Investigators

• Sponsor: Amgen

Publications and helpful links

General Publications

• Zhou Y, Zhang F, Starcevic Manning M, Hu Z, Hsu CP, Chen PW, Peng C, Loop B, Mytych DT, Paiva da Silva Lima G. Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions. Cephalalgia. 2022 Jul;42(8):749-760. doi: 10.1177/03331024221075621. Epub 2022 Mar 10.
• Hiramatsu K, Onizuka Y, Hasebe M, Yoshida R, Numachi Y. Novel Drug for Migraine Prophylaxis: Mode of Action, Efficacy and Safety of Erenumab. Shinryo to Shinyaku (Med Cons New-Remed) 2021:58(11):797-832
• Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Lenz R, Wang Y, Cheng S, Hirama T, Mikol DD. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults. Headache. 2019 Nov;59(10):1731-1742. doi: 10.1111/head.13652. Epub 2019 Oct 14.
• Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Cheng S, Numachi Y, Peng C, Xue F, Mikol DD. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine. Headache. 2021 Apr;61(4):653-661. doi: 10.1111/head.14096. Epub 2021 Mar 25.

Helpful Links

• AmgenTrials clinical trials website

Study record dates

Study Major Dates

• Study Start (Actual): January 6, 2016
• Primary Completion (Actual): September 25, 2017
• Study Completion (Actual): June 5, 2019

Study Registration Dates

• First Submitted: December 11, 2015
• First Submitted That Met QC Criteria: December 11, 2015
• First Posted (Estimate): December 15, 2015

Study Record Updates

• Last Update Posted (Actual): October 12, 2022
• Last Update Submitted That Met QC Criteria: October 3, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Keywords: Headache; Prophylaxis; Migraine Prevention
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Headache Disorders, Primary; Headache Disorders; Migraine Disorders; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Immunologic Factors; Calcitonin Gene-Related Peptide Receptor Antagonists; Antibodies, Monoclonal; Erenumab
• Other Study ID Numbers: 20120309

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
• IPD Sharing Time Frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
• IPD Sharing Access Criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
• IPD Sharing Supporting Information Type: Study Protocol; Statistical Analysis Plan (SAP); Informed Consent Form (ICF); Clinical Study Report (CSR)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes